KARO BIO RESEARCH FOUNDATION AWARDS

The Karo Bio Research Foundation supports academic research within the field of Karo Bios research activities. The first two grants were awarded late 2007 and recently two additional applications have been granted research funding.

In December 2007, the following investigators received research funding:
" Associate Professor Paolo Parini, the Department of Clinical Chemistry, Karolinska University Hospital, Huddinge, received SEK 800 000 for studies on The effects of selective thyromimetics on reverse cholesterol transport and the development of atherosclerosis.
" Dr Margaret Warner and Dr Konstantin Yakimchuk, Department of Biomedical Sciences, Karolinska Institute, Novum Huddinge received SEK 800 000 for Studies of ER² agonists to stimulate immune surveillance: A novel approach for treatment of cancer.

In May 2008 it was decided that the following investigators will receive grants from the foundation;
" Dr Monique Kester, Dept. of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands, will receive EUR 70 000 for studies on The role of type III deiodinase (D3) and thyroid hormone analogs in cellular proliferation.
" Professor Cheryl Frye, the Department of Psychology, University of Albany, USA, has been granted USD 60 000 for studies on The role of estrogen receptor beta as a target for beneficial effects of androgens in an animal model of andropause.

We are pleased to grant these investigators funds to carry out research of great potential importance to Karo Bio. By stimulating and funding academic research groups we hope to advance knowledge in areas that can later be useful in drug development, says Per Olof Wallström, President of Karo Bio and Chairman of the Karo Bio Research Foundation.

For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer
Phone: +46 8 608 60 20

Per Otteskog, Senior Vice President Investor Relations
Phone: +46 8 608 60 18

Erika Johnson, Chief Financial Officer
Phone: +46 8 608 60 52

About Karo Bio
Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals.

The Company has a strong project portfolio with innovative molecules that primarily target metabolic diseases such as diabetes, atherosclerosis and dyslipidemia. In all of these areas there are significant market opportunities and a need for pharmaceuticals with new mechanisms of action. Karo Bio intends to bring selected compounds within niche therapeutic areas into late stage clinical development and, potentially, to the market. In addition to pursuing niche opportunities, Karo Bio
continues to develop compounds aimed at treatment of broad patient populations to clinical proof of concept before out licensing.

In addition to the proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies for development of innovative therapies for the treatment of common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm since 1998 (Reuters: KARO.ST).

About the Karo Bio Research Foundation
The Karo Bio Research Foundation was established in 1994 in relation to liquidation of SGI (Swedish Genetic Investment AB, a former consortium of Karo Bio shareholders). The funds of the Research Foundation originates from a sub-fraction of SGI shares in Karo Bio. The purpose of the foundation is to support research in the field of Karo Bios operations. Recipients of awards must have its research activities outside the Karo Bio Company. Applications can be submitted at any time. Further information can be found at the Karo Bio website:

This press release is also available online at: www.karobio.com and www.newsroom.cision.com